Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04548752
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
- NCT04548752 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on NCT04548752 (olaparib and pembrolizumab in Metastatic Pancreatic Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04548752 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib; Pembrolizumab
- Arms
- Arm A (olaparib, pembrolizumab) · Experimental
- Arm B (olaparib) · Active comparator
- Enrollment
- 68
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Feb 22, 2021
- Primary completion
- Jul 16, 2025
- Results posted
- No
- Registry record
- NCT04548752 · updated Oct 7, 2026